Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

Immutep believes its LAG-3 candidate eftilagimod alpha may have a path to approval in first-line head and neck cancer after ...

First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and ...

Despite a risk for severe side effects, pembrolizumab has a record of improving recurrence-free survival that makes it an appealing treatment for advanced melanoma.

Complementary nature of these two immunotherapies leads to excellent 17.6-month median Overall Survival in head and neck ...

Even when equities are volatile, investors can find great stocks to buy. And the rules for investing in the current ...

Enriqueta Felip, MD, PhD, discusses how results from the phase 3 3475A-D77 trial evaluating subcutaneous pembrolizumab vs ...

New Jersey-based pharmaceutical giant Merck is investing $1 billion in what company executives described as a continued ...

The use of RWD data in place of placebo groups is improving various elements across the clinical trial space.